Kentaro Yoshimatsu
Founder at Rin Institute, Inc.
Profile
Kentaro Yoshimatsu is the founder and President & Representative Director of Rin Institute, Inc. which is founded in 2016.
He is currently a Director at Anaeropharma Science, Inc. Dr. Yoshimatsu was the Chief Scientific Officer & Senior Vice President at Eisai Co., Ltd.
from 1978 to 2011.
He was also the President of H3 Biomedicine, Inc. Dr. Yoshimatsu received his undergraduate, graduate, and doctorate degrees from the University of Tokyo.
Kentaro Yoshimatsu active positions
Companies | Position | Start |
---|---|---|
Anaeropharma Science, Inc.
Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Director/Board Member | - |
Rin Institute, Inc.
Rin Institute, Inc. Pharmaceuticals: MajorHealth Technology Rin Institute, Inc. is a company based in Tokyo, Japan that was founded in 2016 by Kentaro Yoshimatsu. The Japanese company's website simply states that it is "just another WordPress site." | Founder | 2016-01-20 |
Former positions of Kentaro Yoshimatsu
Companies | Position | End |
---|---|---|
EISAI CO., LTD. | Chief Tech/Sci/R&D Officer | 2011-09-29 |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | President | - |
Training of Kentaro Yoshimatsu
University of Tokyo | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
EISAI CO., LTD. | Health Technology |
Private companies | 3 |
---|---|
Anaeropharma Science, Inc.
Anaeropharma Science, Inc. BiotechnologyHealth Technology Anaeropharma Science, Inc. operates as a holding company that engages in the research and development of therapeutics to target hypoxic environment in solid cancers. It develops bifidobacterium technologies to create anti-cancer drugs. The firm's bifidobacterium therapeutics accumulates to the solid tumor when intravenously injected. The company was founded by Minoru Fujimori and Shunichiro Taniguchi on August 9, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
Rin Institute, Inc.
Rin Institute, Inc. Pharmaceuticals: MajorHealth Technology Rin Institute, Inc. is a company based in Tokyo, Japan that was founded in 2016 by Kentaro Yoshimatsu. The Japanese company's website simply states that it is "just another WordPress site." | Health Technology |
- Stock Market
- Insiders
- Kentaro Yoshimatsu